Printer Friendly

Blood Pressure Drug Recalled Due to Cancer Risk.

A November 2nd USA Today article discussed the recall of a blood pressure medication that was recalled due to an impurity linked to cancer. Irbesartan tablets produced by ScieGen Pharmaceuticals are the subjects of the voluntary recall. They were sold in 75, 150, and 300 mg doses and labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc.

The drug, which is prescribed to treat high blood pressure and kidney disease, was found to contain N-nitrosodiethylamine (NDEA). NDEA occurs naturally in certain foods, drinking water, air pollution, and industrial processes and is listed as a probable human carcinogen, according to The International Agency for Research on Cancer. ScieGen noted that the company has not been made aware of any adverse events related to the recall.

COPYRIGHT 2018 PMMI Media Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Healthcare Packaging
Article Type:Brief article
Date:Nov 6, 2018
Previous Article:'Helper Code' Aids Serialization.
Next Article:Verification Router Service Moves from Theoretical to Practical.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters